Senior Director, Corporate Counsel (12 month FTC)

Oxford BioMedica (UK) Limited; Staines-upon-Thames; On-site; GBP 120,000 - 180,000; Full time

Benefits offered by this job

Competitive total rewards

Wellbeing programmes

Career development opportunities

Job summary

Oxford Biomedica is seeking a Senior Director, Corporate Counsel to join its Legal team on a 12‑month fixed‑term contract. You will provide legal advice on corporate and company secretarial matters, partnering with the Chief Legal Officer to protect the Group and enable delivery of its strategy.

The role involves supporting annual reports, FTSE and FCA filings, subsidiary management, governance compliance, debt financing, and corporate transactions, including data subject access requests.

Qualifications

• Qualified solicitor with practising certificate in England & Wales.
• Proven post‑qualification experience in a leading law firm or complex listed/regulatory org.
• UK corporate law expertise including governance, capital markets, M&A, and compliance.
• Ability to translate complex legal developments into practical, risk‑based advice and controls.

Responsibilities

• Assist CLO and Deputy Co Sec with annual reports, interims and corporate updates.
• Assist with FTSE listing requirements and FCA filings.
• Assist with Group subsidiary management.
• Assist with corporate governance compliance with best practice.
• Assist with management of debt financing.
• Assist with corporate transactions as needed.
• Assist with Data Subject Access Requests.

Skills

Corporate governance

Regulatory compliance

M&A

UK corporate law

Education

Qualified solicitor in England & Wales

Job description

About the Role

At OXB, our people are at the heart of everything we do. We’re on a mission to enable life‑changing therapies to reach patients around the world and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. We are currently recruiting for a Senior Director, Corporate Counsel to join our Legal team on a 12‑month fixed‑term contract. In this role, you will provide legal advice on corporate and company secretarial matters, partnering with the Chief Legal Officer to protect the Group, enable delivery of its strategy and maintain high standards of legal compliance playing a key part in advancing our mission and making a real difference.

Responsibilities

• Assist CLO and Deputy Co Sec with annual report/interims/corporate updates
• Assist with FTSE listing requirements and FCA filings
• Assist with Group subsidiary management
• Assist with corporate governance compliance with best practice
• Assist with management of debt financing
• Assist with any corporate transactions, to the extent required
• Assist with Data Subject Access Requests

Requirements

• Qualified solicitor in England and Wales holding a current practising certificate or equivalent professional standing
• Proven post‑qualification experience gained in a leading law firm and/or a complex listed or regulated organisation.
• UK corporate law expertise with experience in governance, capital markets, M&A, compliance and managing complex legal matters
• Ability to translate complex legal and regulatory developments into practical, risk‑based advice and effective organisational controls.

About OXB

OXB is a quality and innovation‑led viral vector CDMO that enables its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA) into a patient’s cells. One highly effective approach to delivering genetic information is to re‑engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patient’s cells. This can be achieved either by directly administering the vector to the patient (in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (ex vivo gene therapy or gene‑modified cell therapy).

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. OXB’s world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.

Why Join Us?

• Competitive total reward packages
• Wellbeing programmes that support your mental and physical health
• Career development opportunities to help you grow and thrive
• Supportive, inclusive, and collaborative culture
• State‑of‑the‑art labs and manufacturing facilities
• A company that lives its values: Responsible, Responsive, Resilient, Respect

We want you to feel inspired every day

At OXB, we’re future‑focused and growing fast. We succeed together through passion, commitment, and teamwork.

Ready to Make a Difference?

Collaborate. Contribute. Change lives.

About Oxford Biomedica

Oxford Biomedica is a quality and innovation‑led viral vector CDMO that enables its clients to deliver life‑changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA) into a patient’s cells. One highly effective approach to delivering genetic information is to re‑engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patient’s cells. This can be achieved either by directly administering the vector to the patient (in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (ex vivo gene therapy or gene‑modified cell therapy).

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno‑associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world‑class capabilities span from early‑stage development to commercialisation. These capabilities are supported by robust quality‑assurance systems, analytical methods and depth of regulatory expertise.